PT-141 (bremelanotide) and MT-2 (Melanotan II) are both synthetic cyclic heptapeptides studied as melanocortin-receptor agonists, but research interest centers on different receptor subtypes.
At a glance
| Property | PT-141 | MT-2 (Melanotan 2) |
|---|---|---|
| Class | Synthetic cyclic heptapeptide | Synthetic cyclic heptapeptide |
| Primary research target | MC3R / MC4R (central) | MC1R and broad melanocortin |
| Research domain | Neuroendocrine signaling | Melanogenesis / pigmentation |
| Structure | Cyclic heptapeptide | Cyclic heptapeptide |
| Format | Lyophilized powder | Lyophilized powder |
PT-141 in research
PT-141 is characterized in preclinical literature as an agonist with research interest at the MC3R and MC4R subtypes, studied in central melanocortin and neuroendocrine-signaling models. See the full PT-141 research profile.
MT-2 (Melanotan 2) in research
MT-2 is characterized as a non-selective melanocortin agonist with research interest in MC1R-mediated melanogenesis signaling and broader melanocortin-pathway activity in pigmentation models. See the full MT-2 (Melanotan 2) research profile.
Key differences
- PT-141 research centers on the central MC3R/MC4R subtypes; MT-2 research includes MC1R pigmentation pathways.
- PT-141 is studied in neuroendocrine-signaling models; MT-2 in melanogenesis models.
- Both share a cyclic-heptapeptide scaffold and are supplied as lyophilized research powders.
Selecting for a research model
Researchers select between PT-141 and MT-2 based on the melanocortin receptor subtype and pathway under study. These distinctions are described strictly in the context of research models and are not statements of efficacy, safety, or suitability for any use.
Both PT-141 and MT-2 (Melanotan 2) ship from Vantage Aminos with a batch-specific Certificate of Analysis (HPLC purity and mass-spectrometry identity), U.S. synthesized for research use.
For research use only. Not for human or veterinary use.
- HPLC + MS tested, every batch
- U.S. synthesized
- Batch COA on the product page
